Please ensure Javascript is enabled for purposes of website accessibility
Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Vaccine vial and syringe

Is Novavax Stock a Buy?

The biotech's growth prospects still appear to clearly outweigh its risks.

Woman patient seeing a female healthcare provider in a doctor's office.

What's Behind Guardant Health's Disappointing Q4 Results

The company beat revenue expectations, but its bottom-line performance and 2021 outlook weren't what investors hoped for.

Cannabis leaf $100 bills

Is GrowGeneration Stock a Buy?

Here are the arguments both for and against the high-flying stock.

shadow of a dollar sign over cannabis leaves

Innovative Industrial Properties' Revenue and Earnings More Than Double in Q4

But the cannabis-focused REIT didn't meet Wall Street's expectations.

Red line falling $100 bill

3 Growth Stocks You'll Want to Buy in the Next Market Crash

Any short-term pullback could present a great opportunity to buy these long-term winners.

Test tubes with green arrow pointing up

Why Poseida Therapeutics Stock Is Popping Today

The biotech reported pipeline progress at its virtual R&D Day.

Doctor wearing gloves and mask

Why Owens & Minor Stock Is Skyrocketing Today

The company announced great Q4 results.

Doctor checking a woman's skin

Why DermTech Stock Is a Buy Right Now

This high-flying healthcare stock should have more room to run.

Older woman about to get vaccine

1 Big Problem Ocugen Could Face That Investors Might Be Overlooking

This issue won't affect just Ocugen.

Cannabis plants in a greenhouse

98 Million Reasons Sundial Growers Isn't a Great Stock to Buy Right Now

Actually, there are a few more than 98 million.

DNA with magnifying glass

Is Fulgent Genetics Still a Good Stock to Buy?

It's a volatile stock right now. But the future for genomic testing looks bright.

pills shaped as dollar signs in packaging

Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results

The company beat top-line estimates, but missed on the bottom line.

Stock chart

Why Has Pfizer Stock Floundered?

There are two main reasons. At least one of them, though, isn't a problem anymore.

Vaccine vials - 2 knocked over and 2 standing

Should Investors Worry About Moderna's Vaccine Delays?

The short answer: No.

Pharmacist wearing mask

Should You Buy CVS Health Stock After Its Q4 Update?

The pharmacy retailer and health insurer topped Wall Street estimates but could face some challenges in 2021.

Physician holding a vaccine shot

What Are Johnson & Johnson's Chances of Success With Its COVID Vaccine?

The clock is ticking until an FDA advisory committee reviews the healthcare giant's vaccine.

Smiling Warren Buffett - TMF

Warren Buffett Just Bought These 2 Dirt-Cheap Stocks. Should You?

Yes -- if you're looking for the same qualities in a stock that the billionaire investor is.

Dog with owners and veterinarian

Why This Pet Stock Is a Better Bet Than Zomedica

It's not that Zomedica is necessarily a bad pick. The chances of long-term success, though, are higher with another stock.

COVID-19 vaccine bottles over $100 bills

2 Reasons Pfizer's COVID Vaccine Prospects Just Got Even Better

The good news keeps on coming.

DNA and image of a head with 1s and 0s

Why Invitae Stock Fell 11.1% Today

There's nothing to be alarmed about.